Literature DB >> 15907584

A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles.

Alf Lamprecht1, Hiromitsu Yamamoto, Hirofumi Takeuchi, Yoshiaki Kawashima.   

Abstract

Nanoparticles (NP) are known to accumulate at the site of inflammation in inflammatory bowel disease. In order to avoid premature uptake or degradation of NP during their passage through the small intestine, it appeared necessary to devise a form of local delivery system for NP. Tacrolimus (FK506) loaded poly(lactic-co-glycolic acid) NP entrapped into pH-sensitive microspheres (NPMS) were designed to achieve greater selectivity to their site of action when administered orally. The therapeutic efficacy of this drug delivery system was tested in an experimental colitis in rats. The in vitro characterization showed a successful incorporation of FK506-NP and strongly pH-sensitive release kinetics of both NP and drug. During the in vivo studies, clinical activity, colon/body weight index, and myeloperoxidase activity were determined to assess the severity of inflammation. Systemic availability of a fluorescent dye entrapped in the microspheres was measured in order to determine possible adverse effects. The NPMS as well as the controls of NP and MS formulations exhibited significant mitigating effects in the clinical activity index after 3 days of treatment with similar levels for the various therapies. When observing colon/body weight index and myeloperoxidase activity, only the NPMS group reached statistically significant differences (P<0.05) compared to the colitis control group while other groups did not (colitis control: 21.94+/-4.97; FK506 solution: 15.81+/-3.42; FK506-NP: 17.03+/-5.52; FK506-MS: 15.17+/-7.81; and FK-NPMS: 10.26+/-7.76 U/mg tissue). Moreover, the NPMS system reduced the systemic absorption of the entrapped dye compared to the dye solution or simple NP formulation (relative biovailability-solution: 100+/-14.9%; NP: 46.8+/-8.6%; and NPMS: 29.4+/-3.3%). The results suggest that the NPMS system can provide selective delivery of NP in the colon and develop a significant mitigating effect, while the control group treatments appeared to be insufficient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907584     DOI: 10.1016/j.jconrel.2005.02.011

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  17 in total

1.  IBD: selective nanoparticle adhesion can enhance colitis therapy.

Authors:  Alf Lamprecht
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06       Impact factor: 46.802

Review 2.  Micro and nanoparticle drug delivery systems for preventing allotransplant rejection.

Authors:  James D Fisher; Abhinav P Acharya; Steven R Little
Journal:  Clin Immunol       Date:  2015-05-01       Impact factor: 3.969

Review 3.  Nanomedicines in gastroenterology and hepatology.

Authors:  Alf Lamprecht
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-10       Impact factor: 46.802

4.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

5.  Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.

Authors:  Hussain Ali; Benno Weigmann; Eva-Maria Collnot; Saeed Ahmad Khan; Maike Windbergs; Claus-Michael Lehr
Journal:  Pharm Res       Date:  2015-12-30       Impact factor: 4.200

6.  Biodistribution and pharmacokinetics of colon-specific HPMA copolymer--9-aminocamptothecin conjugate in mice.

Authors:  Song-Qi Gao; Zheng-Rong Lu; Pavla Kopecková; Jindrich Kopecek
Journal:  J Control Release       Date:  2006-10-27       Impact factor: 9.776

Review 7.  Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases.

Authors:  Davide Prosperi; Miriam Colombo; Ivan Zanoni; Francesca Granucci
Journal:  Semin Immunol       Date:  2017-08-30       Impact factor: 11.130

8.  Delivery of rapamycin to dendritic cells using degradable microparticles.

Authors:  S Jhunjhunwala; G Raimondi; A W Thomson; S R Little
Journal:  J Control Release       Date:  2008-10-26       Impact factor: 9.776

9.  Prevention of vascular-allograft rejection by protecting the endothelial glycocalyx with immunosuppressive polymers.

Authors:  Erika M J Siren; Haiming D Luo; Franklin Tam; Ashani Montgomery; Winnie Enns; Haisle Moon; Lyann Sim; Kevin Rey; Qiunong Guan; Jiao-Jing Wang; Christine M Wardell; Mahdis Monajemi; Majid Mojibian; Megan K Levings; Zheng J Zhang; Caigan Du; Stephen G Withers; Jonathan C Choy; Jayachandran N Kizhakkedathu
Journal:  Nat Biomed Eng       Date:  2021-08-09       Impact factor: 25.671

10.  Formulation strategies for drug delivery of tacrolimus: An overview.

Authors:  Pranav Patel; Hitesh Patel; Shital Panchal; Tejal Mehta
Journal:  Int J Pharm Investig       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.